REGENXBIO Inc. (RGNX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 155 | 470 | 113 | 90 | 83 | 170 | 174 | 164 |
| Operating profit | $m | -161 | -164 | ||||||
| Net profit | $m | -111 | 128 | -280 | -263 | -227 | -194 | -196 | -181 |
| EPS reported | $ | -3.76 | -3.79 | ||||||
| Operating cashflow per share | $ | -2.40 | -4.67 | ||||||
| Capex per share | $ | 0.05 | 0.06 | ||||||
| FCF per share | $ | -2.45 | -4.73 | ||||||
| Free cash flow | $m | -126 | -250 | ||||||
| Net debt | $m | -35 | -106 | ||||||
| Book value equity | $m | 103 | 72 | ||||||
| Book value per share | $ | 1.99 | 1.35 | ||||||
| Number of shares | m | 51.57 | 53.02 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 7.23 | 10.35 | ||||||
| P/S LTM | x | 4.36 | 4.26 | ||||||
| P/FCF LTM | x | -5.88 | -2.97 | ||||||
| EV/EBITDA LTM | x | -7.27 | -6.96 | ||||||
| EV/Sales LTM | x | 5.68 | 3.38 | ||||||
| Earnings Yield LTM | % | -26.11% | -34.55% | ||||||
| FCF Yield | % | -17.02% | -33.62% | ||||||
| Quality | |||||||||
| ROE | % | -188.72% | -220.07% | ||||||
| ROIC | % | -42.11% | -52.72% | ||||||
| Operating margin | % | -94.58% | -94.08% | ||||||
| Gross margin | % | +88.09% | +54.22% | ||||||
| FCF/Sales | % | -74.15% | -143.09% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +104.54% | +109.39% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.49 | -3.62 | ||||||
| Net Debt/EBITDA | x | -1.70 | -0.23 | ||||||
| EBIT/Net interest | x | -3.58 | -3.91 | ||||||
| Net debt/market cap | % | +26.30% | 0.00% | ||||||
| Net debt/Equity | x | -0.34 | -1.47 | ||||||
| Gross debt/equity | x | 2.54 | 0.96 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free